Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros


Bases de dados
Tipo de documento
Intervalo de ano de publicação
2.
Infect Disord Drug Targets ; 17(3): 223-226, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28558644

RESUMO

BACKGROUND: Subcutaneous phaeohyphomycosis is an infection caused by melanized fungi and is increasingly reported among immunosuppressive patients. The most commonly cited etiologic agent is Exophiala jeanselmei, followed by Alternaria spp. We present a case of subcutaneous phaeohyphomycosis in a 48-yearold woman, with a history of lepromatous leprosy, using corticosteroid in immunosuppressive doses due to a type 2 repetitive reaction leprosy outbreak. RESULT AND DISCUSSION: The diagnosis was confirmed by fine-needle aspiration of the secretion, with subsequent direct mycological observations, culture and molecular analysis. The species agent was identified by culture and nucleotide sequences of ribosomal DNA as Exophiala dermatitidis.


Assuntos
Exophiala/isolamento & purificação , Hanseníase Virchowiana/complicações , Feoifomicose/complicações , Feoifomicose/microbiologia , Corticosteroides/uso terapêutico , Biópsia por Agulha Fina , DNA Ribossômico , Exophiala/genética , Feminino , Humanos , Hospedeiro Imunocomprometido , Hanseníase Virchowiana/microbiologia , Pessoa de Meia-Idade , Feoifomicose/diagnóstico
3.
Artigo em Inglês | MEDLINE | ID: mdl-26261143

RESUMO

Cladophialophora bantiana is a neurotropic dematiaceous fungus which only rarely affects the skin. We report a case of disseminated cutaneous phaeohyphomycosis caused by Cladophialophora bantiana in an immunocompromised female who presented with multiple pyogenic granuloma-like nodules, dermatophytosis-like plaque, and subcutaneous cysts on the upper and lower extremities without systemic involvement. Biopsy revealed black yeasts resembling sclerotic bodies and culture yielded irregular, velvety, grey colonies with black reverse. Excision of the nodules and treatment with oral itraconazole 100 mg twice daily resulted in complete clinical resolution within two months, following which itraconazole was administered for another 4 months.


Assuntos
Ascomicetos/isolamento & purificação , Dermatomicoses/diagnóstico , Feoifomicose/diagnóstico , Adulto , Dermatomicoses/complicações , Dermatomicoses/imunologia , Feminino , Humanos , Hospedeiro Imunocomprometido/imunologia , Feoifomicose/complicações , Feoifomicose/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA